Literature DB >> 9481251

Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.

K E Kiley1, D M Gale.   

Abstract

As the incidence of melanoma continues to increase, oncology nurses will be caring for more patients receiving adjuvant alpha interferon-2b. Managing the side effects from this therapy requires expert nursing care. The nurse's role throughout the year-long therapy is critical to ensure the patient's continued adherence to the treatment schedule.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9481251

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  2 in total

Review 1.  Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective.

Authors:  Krista M Rubin; Karen Vona; Kathleen Madden; Suzanne McGettigan; Ilana M Braun
Journal:  Support Care Cancer       Date:  2012-05-05       Impact factor: 3.603

2.  Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma.

Authors:  N Levesque; K Mitchinson; D Lawrie; L Fedorak; D Macdonald; C Normand; J F Pouliot
Journal:  Curr Oncol       Date:  2008-01       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.